Objective:Reveal the material basis and mechanism of angiogenesis effect of Danshen-chuanxiong herb-partners.Methods:The effective components of Danshen and chuanxiong were searched in the TCM System Pharmacology Data...Objective:Reveal the material basis and mechanism of angiogenesis effect of Danshen-chuanxiong herb-partners.Methods:The effective components of Danshen and chuanxiong were searched in the TCM System Pharmacology Database(TCMSP),and the drug targets were searched in the Swiss Target Prediction database;in the Disease-Gene Database(DisGeNET))Search for angiogenesis-promoting and inhibiting angiogenesis targets;use the protein interaction database(STRING)database and Cytoscape software to analyze the network core targets;use the DAVID database to enrich the drug-disease target intersection for GO and KEGG;RT-qPCR experiments verified the effect of luteolin on MMP9 gene expression;in vitro tube formation experiments analyzed the effect of luteolin on endothelial cell neovascularization.Results:After analysis,it is concluded that Danshen has 10 active ingredients and 50 angiogenesis targets;Chuanxiong has 2 active ingredients and 4 angiogenesis targets.The intersection of drug-taking targets yielded 9 targets,including AR,PARP1,MMP9,MMP2,MMP12,AKR1B10,ABCC1,CDK6,and STAT3.After analyzing the active ingredient-target network graph of Danshen/Chuanxiong,it was concluded that luteolin is the key chemical ingredient.After protein interaction(PPI)analysis,the results showed that MMP9 is the core target.The KEGG pathway is mainly enriched in 5 signaling pathways,the most important pathway is cancer-related pathways.There are 22 main biological processes of GO,which mainly involve collagen catabolism,protein extracellular matrix,metal endopeptidase activity,etc.The preliminary analysis of tubule formation experiment shows that luteolin inhibits angiogenesis and down-regulates the expression of MMP9 gene.Conclusion:Luteolin,the key chemical component of the Danshen-Ligusticum chuanxiong drug pair,inhibits angiogenesis by regulating the MMP9 target,and develops the reverse regulation of angiogenesis for the traditional Chinese medicine for promoting blood circulation and removing blood stasis on the basis of the known treatment of ischemic diseases.Provide a new perspective and theoretical basis for the use of Danshen and Chuanxiong medicine in clinical cancer patients.Reveal the material basis and mechanism of angiogenesis effect of Danshen-chuanxiong herb-partners.展开更多
目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床...目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床应用指南》(2021年版)梳理所有活血化瘀类中药注射剂,根据其药品说明书信息、指南信息和临床使用情况,设立评价指标,运用德尔菲法建立评价标准。收集2022年1月1日至6月30日某院心内科活血化瘀类中药注射剂使用数据,采用评价标准结合优劣解距离法(technique for order preference by similarity to an ideal solution,TOPSIS)进行评价。结果 共纳入21种活血化瘀类中药注射剂适应证,分别从适应证、溶媒、用法用量、辅料和溶剂、配伍使用、特殊人群等方面建立一级、二级评价指标。根据评价结果分析120例心内科使用活血化瘀类中药注射剂患者中,相对接近度(Ci)≥60%的有107例(89.17%),表明某院心内科使用活血化瘀类中药注射剂应用情况基本合理。结论 评价标准的建立有利于提高活血化瘀类中药注射剂使用的合理性,可促进活血化瘀类中药注射剂临床的安全使用。展开更多
目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为...目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为慢性心力衰竭的住院患者的病历,按照纳入和排除标准,利用中医传承辅助平台(Traditional Chinese Medicine Inheritance Computer System,TCMICS)V3.0对中药使用频次、用药规律等进行分析;采用网络药理学的方法,筛选出核心药物组合治疗CHF的潜在靶点,初步预测其可能的作用机制。结果共纳入625例患者,787张中药处方。有56味中药使用频次超过50次,主要为补虚药、利水渗湿药及活血化瘀药;结合高频中药、关联规则及聚类分析得到治疗CHF的核心药物组合为:黄芪、党参、茯苓、桂枝、益母草、川芎和赤芍。网络药理学分析表明核心药物组合中槲皮素、异鼠李素等活性成分作用于AKT1、EGFR、MMP9等20个CHF核心靶点;核心药物组合治疗CHF的潜在靶点主要富集在11个细胞组成、17种分子功能和20个生物过程中;生物学通路主要为MAPK信号通路、PI3K-Akt信号通路、AMPK信号通路等。结论中药治疗CHF以益气温阳,利水消肿,活血化瘀为主。核心药物组合可能通过参与心室重塑、炎症反应等过程从而发挥治疗CHF的作用。展开更多
基金Fund Project:Outstanding Doctoral Graduates of Shanxi University of Traditional Chinese Medicine Come to Shanxi to Work,Reward Funds,Scientific Research Start-Up Fund Project(No.2020BKS06)。
文摘Objective:Reveal the material basis and mechanism of angiogenesis effect of Danshen-chuanxiong herb-partners.Methods:The effective components of Danshen and chuanxiong were searched in the TCM System Pharmacology Database(TCMSP),and the drug targets were searched in the Swiss Target Prediction database;in the Disease-Gene Database(DisGeNET))Search for angiogenesis-promoting and inhibiting angiogenesis targets;use the protein interaction database(STRING)database and Cytoscape software to analyze the network core targets;use the DAVID database to enrich the drug-disease target intersection for GO and KEGG;RT-qPCR experiments verified the effect of luteolin on MMP9 gene expression;in vitro tube formation experiments analyzed the effect of luteolin on endothelial cell neovascularization.Results:After analysis,it is concluded that Danshen has 10 active ingredients and 50 angiogenesis targets;Chuanxiong has 2 active ingredients and 4 angiogenesis targets.The intersection of drug-taking targets yielded 9 targets,including AR,PARP1,MMP9,MMP2,MMP12,AKR1B10,ABCC1,CDK6,and STAT3.After analyzing the active ingredient-target network graph of Danshen/Chuanxiong,it was concluded that luteolin is the key chemical ingredient.After protein interaction(PPI)analysis,the results showed that MMP9 is the core target.The KEGG pathway is mainly enriched in 5 signaling pathways,the most important pathway is cancer-related pathways.There are 22 main biological processes of GO,which mainly involve collagen catabolism,protein extracellular matrix,metal endopeptidase activity,etc.The preliminary analysis of tubule formation experiment shows that luteolin inhibits angiogenesis and down-regulates the expression of MMP9 gene.Conclusion:Luteolin,the key chemical component of the Danshen-Ligusticum chuanxiong drug pair,inhibits angiogenesis by regulating the MMP9 target,and develops the reverse regulation of angiogenesis for the traditional Chinese medicine for promoting blood circulation and removing blood stasis on the basis of the known treatment of ischemic diseases.Provide a new perspective and theoretical basis for the use of Danshen and Chuanxiong medicine in clinical cancer patients.Reveal the material basis and mechanism of angiogenesis effect of Danshen-chuanxiong herb-partners.
文摘目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床应用指南》(2021年版)梳理所有活血化瘀类中药注射剂,根据其药品说明书信息、指南信息和临床使用情况,设立评价指标,运用德尔菲法建立评价标准。收集2022年1月1日至6月30日某院心内科活血化瘀类中药注射剂使用数据,采用评价标准结合优劣解距离法(technique for order preference by similarity to an ideal solution,TOPSIS)进行评价。结果 共纳入21种活血化瘀类中药注射剂适应证,分别从适应证、溶媒、用法用量、辅料和溶剂、配伍使用、特殊人群等方面建立一级、二级评价指标。根据评价结果分析120例心内科使用活血化瘀类中药注射剂患者中,相对接近度(Ci)≥60%的有107例(89.17%),表明某院心内科使用活血化瘀类中药注射剂应用情况基本合理。结论 评价标准的建立有利于提高活血化瘀类中药注射剂使用的合理性,可促进活血化瘀类中药注射剂临床的安全使用。
文摘目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为慢性心力衰竭的住院患者的病历,按照纳入和排除标准,利用中医传承辅助平台(Traditional Chinese Medicine Inheritance Computer System,TCMICS)V3.0对中药使用频次、用药规律等进行分析;采用网络药理学的方法,筛选出核心药物组合治疗CHF的潜在靶点,初步预测其可能的作用机制。结果共纳入625例患者,787张中药处方。有56味中药使用频次超过50次,主要为补虚药、利水渗湿药及活血化瘀药;结合高频中药、关联规则及聚类分析得到治疗CHF的核心药物组合为:黄芪、党参、茯苓、桂枝、益母草、川芎和赤芍。网络药理学分析表明核心药物组合中槲皮素、异鼠李素等活性成分作用于AKT1、EGFR、MMP9等20个CHF核心靶点;核心药物组合治疗CHF的潜在靶点主要富集在11个细胞组成、17种分子功能和20个生物过程中;生物学通路主要为MAPK信号通路、PI3K-Akt信号通路、AMPK信号通路等。结论中药治疗CHF以益气温阳,利水消肿,活血化瘀为主。核心药物组合可能通过参与心室重塑、炎症反应等过程从而发挥治疗CHF的作用。
